Objective

It has been aimed to investigate the Galectin-3 (GAL-3) levels and clinical responses after addition of spironolactone as a mineralocorticoid receptor antagonist (MRA) to the current treatment in patients with heart failure with low ejection fraction who received no aldosterone antagonist therapy previously.

Patients and Methods

The study included 112 patients with heart failure who showed left ventricular ejection fraction (EF) of 35% or below, New York Heart Association (NYHA) Class II-IV symptoms and did not receive MRAs in their current treatment. Serum Gal-3 levels, serum BNP level, 6-minute walk test and class level of NYHA were examined before and 6 months after treatment of spironolactone in all patients.

Patients and Methods

The study included 112 patients with heart failure who showed left ventricular ejection fraction (EF) of 35% or below, New York Heart Association (NYHA) Class II-IV symptoms and did not receive MRAs in their current treatment. Serum Gal-3 levels, serum BNP level, 6-minute walk test and class level of NYHA were examined before and 6 months after treatment of spironolactone in all patients.

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. OP-001 An Under-estimated Complication ff Atrial Fibrillation Ablation: Gastroparesis
2. OP-038 Reduction of Eosinophil Percentage may Predict the Mortality from Acute Coronary Syndromes
3. OP-065 Increased Platelet-to-Lymphocyte Ratio is Related to Slow Coronary Flow
4. OP-104 Mid-term Results of TAVI with Use of Different Approaches in Intermediate Risk Patients

Stay updated, free articles. Join our Telegram channel

Join

Full access? Get Clinical Tree